ADRB2 and Parkinson disease: Among the myriad of downstream events triggered by β-AR signaling, α-synuclein expression enhancement has been recently linked to an underlying drug mechanism of β2-AR agonists, drugs shown to be associated with decreased risk in Parkinson’s disease (PD) and beneficial in several PD models14,15.